Fisetin for Anti-Aging

Beyond the specific senolytic application, fisetin is increasingly framed as a broader “longevity flavonoid” whose effects intersect with the major nutrient-sensing pathways that drive aging biology: AMPK activation and mTOR suppression (the same axis as metformin, rapamycin, and caloric restriction), Sestrin family activation, Nrf2-mediated antioxidant defense, mitochondrial biogenesis support, and sirtuin activation. The dietary sources — strawberries at ~160 µg/g, apples, persimmons, kiwis, grapes, onions, cucumbers — deliver typical daily intakes of 1-5 mg from a normal Western diet, far below the 100-1000 mg used in supplemental research protocols. This deep-dive walks through the broader anti-aging framework, the AMPK / Sestrin / mTOR mechanism, the dose discrepancy between dietary and supplemental intake, and the honest framing of where fisetin fits relative to other longevity interventions with stronger or weaker evidence.

Table of Contents

  1. The “Longevity Flavonoid” Framing
  2. Where Fisetin Fits in the Hallmarks of Aging
  3. AMPK Activation and mTOR Suppression
  4. Sestrin Family Signaling
  5. Nrf2 Antioxidant Response and Mitochondrial Protection
  6. Sirtuin Activation
  7. Dietary Sources — Strawberries, Apples, Persimmons, Others
  8. The Dose Discrepancy — Dietary vs Supplemental
  9. Where Fisetin Fits vs Other Longevity Interventions
  10. Combinations — Stacking with Quercetin, Spermidine, Rapamycin
  11. Key Research Papers
  12. Connections

The “Longevity Flavonoid” Framing

The geroscience field has identified a small number of dietary plant compounds with effects across multiple aging-related pathways: resveratrol (from grape skins and red wine, originally framed as a sirtuin activator), spermidine (from wheat germ, soybeans, and aged cheese, an autophagy inducer), quercetin (from onions, apples, capers; a senolytic partner with dasatinib), curcumin (from turmeric, anti-inflammatory and Nrf2 activator), and now fisetin (from strawberries, senolytic and neuroprotective). The general framing is that these compounds modulate the same nutrient-sensing and stress-response pathways that respond to caloric restriction, exercise, and intermittent fasting — arguably the only interventions with rigorous lifespan-extension evidence across multiple model organisms.

Fisetin's entry into this group is recent — primarily after the Yousefzadeh 2018 senolytic paper. Its position in the framework is distinctive in two ways. First, it is the only one of these compounds for which a single mechanism (senolytic) has produced lifespan extension in mice when administered late in life. Second, its multi-pathway effect profile — AMPK, Nrf2, BCL-xL inhibition, BDNF upregulation — matches the geroscience preference for “hub molecules” that modulate networks rather than single targets.

The marketing position has run further than the evidence. The honest scientific framing is that fisetin is a promising late-life intervention with strong preclinical evidence and pending human efficacy data. It is not yet a proven longevity intervention. The pages on the senolytic mechanism, brain health, and inflammation each cover one aspect of why fisetin produces effects across the aging spectrum.

Back to Table of Contents

Where Fisetin Fits in the Hallmarks of Aging

The Lopez-Otin et al. 2013 (and 2023 updated) framework identifies twelve hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis. Fisetin has plausible mechanism-of-action evidence for effects on at least six of these:

The mechanistic breadth is part of what makes fisetin interesting to the geroscience community. Most pharmacologic candidates target one or two hallmarks; fisetin appears to gently modulate several in parallel, which is the integrated-intervention strategy that aging biology increasingly favors over single-target drug development.

Back to Table of Contents

AMPK Activation and mTOR Suppression

The single most-validated longevity pathway in model organisms is the AMPK / mTOR axis. AMP-activated protein kinase (AMPK) is a cellular energy sensor — it is activated when ATP levels fall and AMP rises, signaling that the cell needs to conserve energy and switch from anabolic to catabolic metabolism. AMPK activation:

The interventions with the strongest longevity evidence in mammals — caloric restriction, intermittent fasting, exercise, metformin, rapamycin — all activate AMPK or suppress mTOR directly. Fisetin activates AMPK at concentrations achievable with supplementation, and this AMPK activation explains many of the secondary effects (autophagy, mitochondrial biogenesis, anti-inflammatory).

The clinical implication is that fisetin sits in the same metabolic-pathway class as metformin and rapamycin — the two most-studied pharmacologic longevity interventions in humans. The differences are significant: metformin has decades of safety data and large human evidence for diabetes outcomes but only emerging evidence for non-diabetic aging applications. Rapamycin has the strongest preclinical longevity evidence but significant immunosuppressive side effects at chronic dosing. Fisetin has weaker human evidence than either but appears better-tolerated than rapamycin.

Back to Table of Contents

Sestrin Family Signaling

The Sestrin family (Sestrin1, Sestrin2, Sestrin3) is a less-publicized but mechanistically important group of stress-induced proteins that sit at the intersection of AMPK and mTOR signaling. Sestrins are upregulated by:

When activated, Sestrins inhibit mTORC1 (reinforcing AMPK's mTOR-suppressing effect) and trigger antioxidant gene expression through Nrf2. The Sestrin pathway is conserved from flies to mammals and Sestrin loss accelerates many age-related phenotypes.

Fisetin's Sestrin activation is part of the broader nutrient-sensing modulation it produces. The effect is most relevant in the context of caloric excess and metabolic dysfunction (modern Western diet patterns), where Sestrin activation can partially compensate for the absence of natural caloric restriction. This is one mechanism by which fisetin and other geroscience polyphenols may be especially useful in metabolically-overloaded older adults.

Back to Table of Contents

Nrf2 Antioxidant Response and Mitochondrial Protection

Nuclear factor erythroid 2-related factor 2 (Nrf2) is the master transcriptional regulator of the body's endogenous antioxidant defense. Under normal conditions Nrf2 is bound to its inhibitor KEAP1 in the cytoplasm and rapidly degraded. Under oxidative stress (or in the presence of Nrf2-activating phytochemicals like sulforaphane, curcumin, and fisetin), Nrf2 is released, translocates to the nucleus, and drives expression of:

The net effect is a dramatic increase in the cell's ability to neutralize reactive oxygen species, detoxify xenobiotics, and protect against the oxidative damage that drives the aging process. The Nrf2 pathway is one of the most-actively-targeted in geroscience drug development.

Fisetin's Nrf2 activation is shared with several other dietary polyphenols and contributes to the antioxidant and mitochondrial-protective effects. The mitochondrial protection is mechanistically downstream — better antioxidant defense reduces oxidative damage to mitochondrial membranes and DNA, preserving electron transport chain function and ATP production. Aged mitochondria show reduced membrane potential, increased ROS production, and reduced ATP output. Fisetin partially reverses these changes in cell culture and in aged-mouse tissue.

For the broader oxidative-stress context, see our Oxidative Stress page.

Back to Table of Contents

Sirtuin Activation

The sirtuin family (SIRT1 through SIRT7 in mammals) are NAD+-dependent deacetylases that respond to cellular energy status and regulate transcription, DNA repair, and metabolic homeostasis. Sirtuin activation has been a major focus of longevity drug development since the early 2000s, when resveratrol was originally framed as a sirtuin activator (a framing that has been substantially complicated by subsequent research).

Fisetin activates SIRT1 (the most-studied of the sirtuins) at supplemental concentrations. SIRT1 activation:

The clinical evidence for SIRT1 activation as a longevity intervention is more contested than the marketing suggests. Direct SIRT1 activators like the original sirtris compounds (SRT1720, SRT2104) have had mixed clinical results. The integrated effect of fisetin on multiple pathways including SIRT1 is more plausible mechanistically than a single-target SIRT1 activation strategy.

Back to Table of Contents

Dietary Sources — Strawberries, Apples, Persimmons, Others

The Phenol-Explorer database and the original Arai 2000 dietary flavonol survey identify the following as the major dietary sources of fisetin (approximate fresh-weight concentrations):

The strawberry dominance is striking — strawberries contain approximately six times more fisetin per gram than the next-richest food (apples). Even a single 150-gram strawberry serving exceeds the total fisetin content of most other foods combined in a typical day.

The dietary intake estimation is approximately 1-5 mg per day in a typical Western diet, with most of the intake coming from apples (the most-consumed source) rather than strawberries (the most-concentrated source). Heavy strawberry consumers can reach 20-30 mg per day in season.

For more on strawberries as a dietary source of fisetin and other beneficial compounds, see our Strawberries page. For other berry sources, see Blueberries.

Back to Table of Contents

The Dose Discrepancy — Dietary vs Supplemental

The single most important practical question is the gap between dietary fisetin intake (~1-5 mg/day) and the doses used in research (~100-1500 mg/day for supplemental, or ~20 mg/kg for senolytic pulses). The dose discrepancy is roughly two to three orders of magnitude.

Three possibilities for interpretation:

  1. Dietary intake produces meaningful but small benefits — this is the position supported by epidemiologic studies of total flavonoid intake and cardiovascular / cognitive outcomes. Heavy fruit consumers do show modest mortality and disease benefits, and some of that benefit may be attributable to fisetin among the broader flavonoid mix. This is the “eat your strawberries” reading.
  2. Supplemental doses produce qualitatively different effects than dietary intake — this is the position supported by the senolytic data. Senescent-cell clearance requires the supraphysiologic concentrations that only supplementation provides. Dietary intake does not reach the thresholds needed to trigger senolysis. This is the “take Novusetin if you want the senolytic effect” reading.
  3. Most of the supplemental claims are overstated and dietary intake captures most of the actual benefit — this is the skeptical position. The animal data uses doses (translated to human equivalents of 1000+ mg) that are achievable with supplementation but produce off-target effects that may not be desirable in long-term use.

The honest position is that both supplementary and dietary intake probably contribute, with supplementary being necessary for the specific senolytic application and dietary being sufficient for the broader background “flavonoid intake” benefit. A reasonable practical approach is to include strawberries, apples, and other fisetin-containing fruits regularly as part of overall fruit-and-vegetable intake, and to add intermittent supplemental dosing for specific senolytic protocols if the individual chooses based on the preliminary evidence.

Back to Table of Contents

Where Fisetin Fits vs Other Longevity Interventions

Honest comparison with the main competing or complementary longevity interventions:

The integrated longevity stack favored by many practitioners includes (varying combinations of): caloric restriction or intermittent fasting, regular exercise, metformin (in diabetics or in some non-diabetic protocols), low-dose rapamycin (off-label), an NAD+ precursor, spermidine, and intermittent senolytic dosing (fisetin or D+Q). No randomized trial has tested this combined approach. Each component has at least preliminary individual evidence.

Back to Table of Contents

Combinations — Stacking with Quercetin, Spermidine, Rapamycin

Common combinations and their rationale:

For the broader longevity protocol context, see our Longevity Protocols page.

Back to Table of Contents

Key Research Papers

  1. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. (2018). Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36:18-28. — PubMed
  2. Khan N, Syed DN, Ahmad N, Mukhtar H (2013). Fisetin: a dietary antioxidant for health promotion. Antioxidants & Redox Signaling 19:151-162. — PubMed
  3. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013). The hallmarks of aging. Cell 153:1194-1217. — PubMed
  4. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2023). Hallmarks of aging: an expanding universe. Cell 186:243-278. — PubMed
  5. Arai Y, Watanabe S, Kimira M, et al. (2000). Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol. Journal of Nutrition 130:2243-2250. — PubMed
  6. Pal HC, Pearlman RL, Afaq F (2016). Fisetin and its role in chronic diseases. Advances in Experimental Medicine and Biology 928:213-244. — PubMed
  7. Fisetin and AMPK activation in metabolic tissues — PubMed
  8. Fisetin and SIRT1 activation in vascular and metabolic models — PubMed
  9. Fisetin and mitochondrial biogenesis through PGC-1α — PubMed
  10. Sestrin family proteins in longevity and aging biology — PubMed
  11. Caloric restriction, AMPK / mTOR signaling, and lifespan extension — PubMed
  12. Phenol-Explorer database fisetin content survey — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents